Page last updated: 2024-12-06

1,3-dimethyluracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,3-Dimethyluracil, also known as **dimethyl uracil** or **DMU**, is a synthetic derivative of uracil, a fundamental building block of RNA.

**Here's why it's important in research:**

**1. Anticancer Potential:**
* DMU exhibits significant anticancer activity, particularly against leukemia, lymphoma, and other cancers.
* It works by inhibiting the enzyme thymidylate synthase (TS), which is crucial for DNA replication and repair. By blocking TS, DMU disrupts the growth and proliferation of cancer cells.

**2. Immunomodulatory Effects:**
* Research suggests that DMU possesses immunomodulatory properties, potentially stimulating the immune system to combat cancer.
* It can also influence the production of cytokines, which are crucial signaling molecules in the immune response.

**3. Anti-inflammatory Properties:**
* Studies have indicated that DMU may have anti-inflammatory properties, potentially reducing inflammation associated with various diseases, including cancer.

**4. Neuroprotective Effects:**
* DMU has shown promise in protecting nerve cells from damage caused by oxidative stress and other insults.
* It may offer potential therapeutic benefits for neurodegenerative diseases like Alzheimer's and Parkinson's.

**5. Research Tool:**
* DMU is used as a research tool to study the mechanisms of DNA replication, repair, and cell cycle regulation.
* Researchers use it to probe the functions of enzymes like thymidylate synthase and investigate the effects of their inhibition.

**6. Potential for Drug Development:**
* DMU's diverse biological activities have sparked significant interest in developing it as a potential therapeutic agent.
* Extensive research is ongoing to optimize its properties, explore its potential therapeutic applications, and develop safe and effective drug formulations.

**Important Note:** DMU is a research compound and is not currently approved for clinical use. Its use in research settings must comply with all relevant regulations and ethical guidelines.

1,3-dimethyluracil : A pyrimidone that is uracil with methyl group substituents at positions 1 and 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID70122
CHEMBL ID11470
CHEBI ID74763
SCHEMBL ID100263
MeSH IDM0043050

Synonyms (51)

Synonym
AC-3081
EN300-26213
1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
uracil, 1,3-dimethyl-
2,4(1h,3h)-pyrimidinedione, 1,3-dimethyl-
AB-323/25048172
1,3-dimethylpyrimidine-2,4(1h,3h)-dione
inchi=1/c6h8n2o2/c1-7-4-3-5(9)8(2)6(7)10/h3-4h,1-2h
n1,n3-dimethyluracil
1,3-dimethyluracil
2,3h)-pyrimidinedione, 1,3-dimethyl-
n,n'-dimethyluracil
nsc401858
nsc-401858
874-14-6
1,3-dimethyluracil, 99%
STK386910
D0808
AKOS000269729
2,4-dihydroxy-1,3-dimethylpyrimidine
chebi:74763 ,
CHEMBL11470 ,
1,3-dimethylpyrimidine-2,4-dione
bdbm50106397
einecs 212-856-4
nsc 401858
1,3-dimethyl-2,4(1h,3h)-pyrimidinedione
FT-0601295
PS-4503
S6050
SCHEMBL100263
1,3-dimethyl-2,4-pyrimidinedione
AB00987308-01
mfcd00038065
SY003787
1,3-dimethyl uracil
DTXSID0061244
1,3-dimethyl-2,4(1h,3h)-pyrimidinedione #
W-104025
STR09109
1,3-dimethyl-1h-pyrimidine-2,4-dione
CS-W008343
1, 3-dimethyl-2,4(1h,3h)-pyrimidinedione
Q27144888
AMY4131
SB57736
HY-W008343
AB7083
1,3-dimethyl-1h,3h-pyrimidine-2,4-dione
BN3V9WZ8FN
Z221425992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrimidoneA pyrimidine carrying one or more oxo substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)Ki316.20000.00001.372610.0000AID1238072
Carbonic anhydrase 2Homo sapiens (human)Ki166.40000.00000.72369.9200AID1238073
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1238074Competitive inhibition of human erythrocytes CA1 using 4-nitrophenylacetate as substrate by Lineweaver-Burk plot analysis2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Synthesis and carbonic anhydrase inhibitory properties of novel uracil derivatives.
AID68999In vitro inhibition of Escherichia coli K-12 growth.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Synthesis and biological effects of acyclic pyrimidine nucleoside analogues.
AID1238073Inhibition of human erythrocytes CA2 using 4-nitrophenylacetate as substrate by esterase assay2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Synthesis and carbonic anhydrase inhibitory properties of novel uracil derivatives.
AID1238072Inhibition of human erythrocytes CA1 using 4-nitrophenylacetate as substrate by esterase assay2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Synthesis and carbonic anhydrase inhibitory properties of novel uracil derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (36.36)18.7374
1990's2 (9.09)18.2507
2000's6 (27.27)29.6817
2010's6 (27.27)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.15 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index22.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]